## **Dr. Dieter Becker**

Industrial Pharmacist



Dr. Dieter Becker studied Pharmacy at the University of Freiburg in Germany and got his licensure as Pharmacist in 1984. He finished 1988 his thesis in pharmaceutical technology at the University of Freiburg on oxygen-transporting blood replacement fluids.

After the thesis he worked for several years as a laboratory head at Ciba-Geigy in Switzerland on solid dosage forms. During this time he could develop several products that were successfully launched (Cibacen <sup>®</sup>, Femara <sup>®</sup>, Banzel <sup>®</sup>).

After the merger of Ciba-Geigy and Sandoz to Novartis (1997) Dr. Becker was several years responsible as a group head (supervision about 15 co-workers) for the development of solid dosage forms in early and late phase development up to hand-over to production e.g. Diovan ® tablets, Gleevec ® capsules, Myfortic ® tablets. He had also own projects like Coartem ®, Egaten ®, Stalevo ®. After 7 years he had the opportunity to extend his knowledge on life-cycle management (LCM) of Novartis drug products by leading technical feasibility studies with drug delivery companies comprising technical, legal, IP and business aspects (Voltaren ® soft-gelatin capsules). He also was assessing more than 100 drug delivery technologies from external companies and evaluating the Novartis drug product portfolio for LCM opportunities.

In his 25 years in pharmaceutical industry he worked on or supervised more than 100 product developments in all phases from research to market introduction from which 7 products where launched under his lead and published several scientific articles and patents.

Dr. Becker retired April 2013 and founded the consultancy company Vivo Drug Delivery GmbH in May 2013.

He supported as a consultant several mid-sized Pharma companies on difficult to formulate drugs and drug products.

In 2021 Dr. Becker decided to close the company. Since Feb 2019 he worked for the NGO Waisenmedizin eV and was elected as 2. Chairmen May 2019.

All mentioned trademarks belong to Novarits Pharma AG; except Banzel from Eizo (licensed out from Ciba-Geigy AG) and Stalevo (Orion Pharma & Novartis)